RxDoctor Payments Data

Dominic Nkwocha, MD

Psychiatry · Smyrna, GANPI 1942221718

Payments from drug & device makers

$5,311in general payments, 2019–2025

Across 62 payments — averaging $85.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neuronetics, Inc.$4K
  • Johnson & Johnson$386
  • Otsuka America Pharmaceutical, Inc.$198
  • Vanda Pharmaceuticals Inc.$82
  • E.r. Squibb & Sons, L.L.C.$75
  • Idorsia Pharmaceuticals US Inc$75
  • plus $412 from 10 others

What the payments were for

  • Food & beverage$1,25524%
  • Education$50%
  • Other$4,05076%

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,311 in reported general payments places this provider in the 85th percentile of 900 psychiatry providers in Georgia.

See all psychiatry providers in Georgia

Medicare billing

Part B allowed, 2024
$97,913
Medicare patients
88
Services billed
1,111

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate34$66,700
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl109$27,198
SuboxoneBuprenorphine Hcl/Naloxone Hcl14$11,292
TrintellixVortioxetine Hydrobromide19$11,082
CymbaltaDuloxetine Hcl25$10,848
Quetiapine Fumarate275$5,170
Duloxetine Hcl267$4,536
Aripiprazole69$4,144
Bupropion XlBupropion Hcl120$2,993
Buprenorphine Hcl49$2,808
Divalproex Sodium ErDivalproex Sodium52$2,511
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine73$2,132
Clonazepam259$1,923
Trazodone Hcl245$1,681
Risperidone151$1,656

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$386$66,70034 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$71$11,08219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 900 psychiatry providers in Georgia.

Other psychiatry in Smyrna

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →